Does Humana Cover Weight Loss Drugs? Honest Coverage Review

Short version: Humana is overwhelmingly a Medicare insurer — Medicare Advantage prescription-drug (MA-PD) plans plus standalone Part D (PDP) plans make up the large majority of its book. That single fact decides most of the answer. Under the federal Medicare Part D statute, drugs “used for… weight loss” are excluded from coverage, so Wegovy, Zepbound, and Saxenda prescribed for weight loss only are not covered by a Humana Medicare plan, no matter how much medical necessity is documented. The realistic Humana coverage paths are the carve-in indications: GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus), Zepbound for obstructive sleep apnea (FDA-approved 12/20/2024), and Wegovy for cardiovascular risk reduction (FDA-approved 3/8/2024) — each with prior authorization. Humana's small commercial/employer book varies, and Humana Medicaid defers to the state.

At a glance

• Humana is a Medicare-first insurer. The large majority of Humana members are in Medicare Advantage prescription-drug (MA-PD) plans or standalone Part D (PDP) plans, so the federal Part D rules — not commercial formulary discretion — drive most coverage outcomes.
• Weight-loss-only GLP-1s (Wegovy, Zepbound, Saxenda): NOT covered on Humana Medicare plans. Federal Part D excludes “agents when used for… weight loss.”^[1] Pharmacy claims submitted with an obesity ICD-10 code (E66.x) auto-reject; only a covered indication code (diabetes E11.x, OSA G47.33, etc.) clears.
• GLP-1s for type 2 diabetes: generally YES with prior authorization. Ozempic, Mounjaro, Trulicity, Victoza, and Rybelsus appear on most Humana Part D formularies for the T2D indication.^[2]
• Zepbound for obstructive sleep apnea: potentially YES with PA. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity on 12/20/2024; because OSA is not a weight-loss indication, the Part D exclusion does not apply.^[5]
• Wegovy for cardiovascular risk reduction: potentially YES with PA. The FDA approved Wegovy to reduce major adverse cardiovascular events in adults with established CVD plus overweight/obesity on 3/8/2024 (SELECT trial); this non-weight-loss indication is coverable on Part D, though individual Humana formularies vary.^[4][8]
• Medicare GLP-1 Bridge (new): starting July 1, 2026, eligible Part D members can get Wegovy, Zepbound, or Foundayo for weight loss at a flat ~$50 copay per 30-day supply, through a CMS demonstration that runs outside the standard Part D benefit.^[6]
• Humana commercial/employer plans: a small minority of the book; anti-obesity-medication coverage varies and is frequently carved out by employer groups.
• Humana Medicaid: where Humana operates Medicaid managed care, weight-loss GLP-1 coverage defers to the state Medicaid program's drug list.
• Pharmacy benefit: Humana administers pharmacy in-house via Humana Pharmacy Solutions, with CenterWell Pharmacy (formerly Humana Pharmacy) and CenterWell Specialty Pharmacy as the mail-order and specialty arms.^[3]

Why Humana is a Medicare-coverage question first

Most write-ups about “does my insurer cover Wegovy” assume a commercial employer plan where the answer turns on the employer's benefit design and the PBM's formulary. Humana is different. The large majority of Humana's medical membership is in Medicare products — Medicare Advantage prescription-drug plans (MA-PD) and standalone Part D drug plans (PDP). That means the first and most important filter is not Humana's discretion at all; it is federal Medicare Part D law.

Section 1860D-2(e)(2)(A) of the Social Security Act lists categories of drugs that Part D plans may exclude from coverage, and among them are “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain.”^[1] In practice every Part D plan, Humana included, excludes weight-loss-only anti-obesity medications. This is not a Humana policy choice that medical-necessity documentation can overturn — it is a statutory exclusion baked into the Medicare drug benefit.

So the structure of the Humana answer is: identify whether you are on a Medicare plan (most members) or a commercial/Medicaid plan (a minority), then identify the indication the prescription is written for. Indication is what unlocks or blocks coverage on Medicare — not BMI, not how badly you want the drug.

GLP-1 coverage for type 2 diabetes (the widely covered path)

Type 2 diabetes is not a weight-loss indication, so the Part D exclusion does not touch it. Across Humana's MA-PD and PDP formularies, GLP-1 receptor agonists for T2D are generally on-formulary with prior authorization:

• Ozempic (semaglutide) — once-weekly injection, FDA-approved for T2D + cardiovascular risk reduction in T2D with established CVD.
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1, FDA-approved for T2D.
• Trulicity (dulaglutide) — once-weekly GLP-1, FDA-approved for T2D + CV risk reduction.
• Victoza (liraglutide) — daily GLP-1, FDA-approved for T2D; older agent with branded and authorized-generic forms.
• Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D.

Typical Humana PA criteria for a T2D GLP-1: a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C, usually a trial of metformin (or documented intolerance/contraindication), and prescriber documentation of treatment goals. Since June 2023 Humana has required pharmacies to submit the diagnosis code on GLP-1 claims, so a claim coded for obesity (E66.x) rather than diabetes (E11.x) auto-rejects at the point of sale. For drug-level reference data, see our semaglutide drug page and tirzepatide drug page.

Weight-loss-only GLP-1s on Humana Medicare (excluded)

The three FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3.0 mg) — when prescribed for weight loss are not covered on a Humana Medicare plan. The mechanism is concrete: Humana's pharmacy claims system reads the submitted ICD-10 code, and an obesity code (E66.x) on a weight-loss GLP-1 returns a rejection consistent with the Part D excluded-drug rule.^[1] No prior authorization will overturn it, because PA decides medical necessity within a covered benefit; here the benefit itself excludes the use.

This is the single most important thing for a Humana Medicare member to understand: the barrier is statutory, not clinical. The productive move is not to fight the weight-loss denial but to determine whether a different, FDA-approved indication applies — OSA or cardiovascular risk reduction — or to use the new Medicare Bridge program described below.

The carve-in indications Humana Medicare CAN cover

Two distinct, FDA-approved, non-weight-loss indications turn the same molecules into coverable Part D drugs:

• Zepbound for moderate-to-severe obstructive sleep apnea. The FDA approved this indication on December 20, 2024, making Zepbound the first drug approved for OSA in adults with obesity. Because OSA is not a weight-loss indication, the §1860D-2(e)(2)(A) exclusion does not apply, and a Humana Medicare plan can cover Zepbound for OSA subject to PA — typically requiring a sleep-study-confirmed AHI ≥ 15 alongside obesity. The SURMOUNT-OSA trial is the underlying evidence base.^[5][7]
• Wegovy for cardiovascular risk reduction. The FDA approved this indication on March 8, 2024, for adults with established cardiovascular disease and overweight or obesity, based on the SELECT trial.^[4][8] As a non-weight-loss indication it is technically coverable on Medicare Part D — though individual Humana formularies vary in how they tier and PA it. Confirm on your specific plan's formulary.

Practically: if you have a documented moderate-to-severe OSA diagnosis or established CVD, the carve-in indication is the realistic Humana path to a GLP-1 — and your prescriber should write and code the prescription to the qualifying indication, not to weight loss.

The Medicare GLP-1 Bridge program (new for July 2026)

Separately from the standard Part D benefit, CMS launched a temporary Medicare GLP-1 Bridge demonstration. Starting July 1, 2026 and running through December 31, 2027, eligible Medicare Part D members can obtain a weight-loss GLP-1 at a flat copay of roughly $50 per 30-day supply, regardless of dose.^[6]

• Drugs covered: Wegovy (injection and tablet), Zepbound (KwikPen), and Foundayo. ^[6]
• Eligibility: reported as BMI ≥ 35 alone, or BMI ≥ 27 with qualifying clinical criteria — confirm the final CMS criteria for your situation.
• Structure: you must be enrolled in Medicare Part D to participate, but the program operates outside the standard Part D benefit. Prescriptions route through a central CMS system for prior authorization, and the $50 copay does not count toward the Part D deductible or the annual out-of-pocket cap.^[6]
• What comes next: a longer-term demonstration (the BALANCE Model) is slated to follow; details and plan participation are still developing.^[6]

For a Humana Medicare member who wants a weight-loss GLP-1 and does not have an OSA or CVD indication, the Bridge program is the one near-term covered route — at a far lower cost than cash-pay. Confirm directly with Humana and with your prescriber whether your plan and clinical profile qualify once the program opens.

Humana commercial, FEHB, and Medicaid plans (the minority book)

A smaller share of Humana members are in commercial/employer plans rather than Medicare. There, the federal Part D exclusion does not apply, and anti-obesity-medication (AOM) coverage is a benefit-design decision:

• Commercial / employer-sponsored: AOM coverage varies. Some employer groups include Wegovy/Zepbound with PA; many carve AOMs out entirely to control premium cost. The authoritative source is your plan's formulary and Summary of Benefits and Coverage (SBC).
• Humana Medicaid managed care: where Humana administers a state Medicaid plan, weight-loss GLP-1 coverage defers to the state Medicaid drug list. Some states cover AOMs; others exclude them. T2D coverage is generally retained regardless.

Typical commercial PA criteria when the plan covers AOMs: BMI ≥ 30, OR BMI ≥ 27 with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or — for Zepbound — moderate-to-severe OSA), age 18+, and documentation of a behavioral/dietary intervention. For how this compares to an integrated HMO model, see our Kaiser Permanente weight-loss coverage article.

How to find out if YOUR Humana plan covers a GLP-1

Four reliable ways, fastest to most authoritative:

1. Humana.com Drug List / formulary search. Sign in, select your specific plan, and search “Wegovy,” “Zepbound,” or “Ozempic.” The result shows the tier, whether prior authorization is required, and any step-therapy or quantity limits.^[2]
2. Phone Humana Member Services / Pharmacy. Use the number on the back of your card and ask specifically: “Is (drug) covered on my plan for (indication)? What is the copay tier, the PA requirement, and the diagnosis code my pharmacy must submit?”
3. Ask your prescriber to run a benefits/PA check. For Medicare members the indication coded on the prescription is decisive; have your prescriber confirm whether you qualify under T2D, OSA, or CVD before the prescription is sent.
4. Request the Evidence of Coverage (EOC) / SBC. The EOC (Medicare) or SBC (commercial) is the controlling document and lists excluded benefits explicitly. For employer plans, HR or the benefits administrator can provide it.

Prior authorization and appeals on Humana

When the prescription is for a covered indication (T2D, OSA, or CVD), PA is the gate. The prescriber submits clinical documentation — diagnosis code, supporting labs or sleep study, prior-therapy history — to Humana Pharmacy Solutions. If Humana denies, Medicare members have a defined federal appeal pathway:

1. Coverage determination / redetermination. First, request a coverage determination; if denied, file a Level 1 appeal (redetermination) with the plan, typically within 60 days of the denial notice. The prescriber can submit a supporting statement of medical necessity.
2. Independent Review Entity (IRE). If the plan upholds the denial, a Level 2 appeal goes to a CMS-contracted Independent Review Entity that is independent of Humana.
3. Higher Medicare appeal levels. Beyond the IRE, the Medicare appeals process continues to an Administrative Law Judge, the Medicare Appeals Council, and ultimately federal court, with dollar-amount thresholds at the higher levels.
4. Commercial / employer plans follow the plan's internal appeal levels and then an external independent review (state IRO, or the federal ERISA framework and U.S. Department of Labor for self-funded employer plans).

Key point for Humana Medicare members: appealing a weight-loss-only denial will not succeed, because the exclusion is statutory. Appeals are worth pursuing when the denial is on a covered indication (e.g., an OSA or CVD prescription denied on documentation grounds), not when the issue is the weight-loss exclusion itself.

If Humana excludes it — what actually works

Ranked by cost, the practical options if you are on Humana Medicare without a covered indication:

• The Medicare GLP-1 Bridge (from 7/1/2026). If you qualify, this is the cheapest covered weight-loss route at roughly $50/month for Wegovy, Zepbound, or Foundayo.^[6]
• The OSA pathway (Zepbound). If you have a sleep-study-confirmed moderate-to-severe OSA diagnosis (AHI ≥ 15) plus obesity, your prescriber can submit a Zepbound PA for the OSA indication — the Part D exclusion does not apply.^[5]
• The CVD pathway (Wegovy). If you have established cardiovascular disease plus overweight/obesity, your prescriber can submit a Wegovy PA for cardiovascular risk reduction.^[4]
• Manufacturer cash-pay self-pay pharmacies. LillyDirect Self Pay (Zepbound vials) and NovoCare Self Pay (Wegovy) sell single-dose vials below brand-retail; cash-pay, no insurance involvement.
• Compounded tirzepatide or semaglutide via verified 503A telehealth. Typically $149-$349/month. Not brand Wegovy or Zepbound — the active ingredient is the same, but quality and supply-chain rigor vary widely; diligence matters. To compare reputable telehealth options, see our best semaglutide providers and best tirzepatide providers rankings.

For mechanism-of-action context and the underlying weight-loss magnitudes (STEP-1 semaglutide -14.9% body weight at 68 weeks^[9]; SURMOUNT-1 tirzepatide 15 mg -20.9% at 72 weeks^[10]), plus the broader payer landscape, see our insurance coverage hub.

Verdict — what most Humana members should expect

For the median Humana member asking does Humana cover weight-loss drugs, the answer is shaped by the fact that most Humana members are on Medicare:

1. Weight-loss-only Wegovy/Zepbound/Saxenda on a Humana Medicare plan: NO. Federal Part D excludes weight-loss drugs; no PA or appeal overturns it.
2. GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus): generally YES with PA, on most Humana Part D formularies.
3. Zepbound for moderate-to-severe OSA (post-12/20/2024) and Wegovy for cardiovascular risk reduction (post-3/8/2024): potentially YES with PA — these are the realistic Humana carve-in paths.
4. Medicare GLP-1 Bridge (from 7/1/2026): the new near-term covered route to a weight-loss GLP-1 at ~$50/month, if you qualify.
5. Humana commercial/Medicaid (minority of members): varies — commercial depends on employer benefit design; Medicaid defers to the state.

The decisive variable on Humana is rarely the formulary tier and almost always the indication and the plan type. Get the indication right (diabetes, OSA, or CVD), confirm your plan type, and check whether the Bridge program applies — that sequence determines coverage far more than any prior-authorization paperwork.

Further reading

• Does Kaiser Permanente cover weight-loss drugs?
• GLP-1 insurance coverage hub